Organon earnings on deck as Sun Pharma deal looms
Organon & Co. is preparing to release its third-quarter earnings on Monday as the company anticipates the completion of its $11.75 billion acquisition by Sun Pharmaceutical. The pending deal has been a significant factor driving investor expectations as the report nears. Analysts anticipate earnings of $0.94 per share and revenue of $1.57 billion for the September quarter, indicating a 6.9% decline in earnings and a 1.9% decrease in revenue compared to the corresponding period last year.
Sequentially, the forecast represents an improvement over the previous quarter, which reported earnings of $0.85 per share and revenue of $1.60 billion. Sun Pharmaceutical initially agreed to pay $14.00 per share for Organon in April, with the deal expected to close in early 2027. As of Friday, shares of Organon closed at $13.89, slightly below the offer price.
Analysts currently maintain a neutral consensus rating on Organon's stock, with a mean price target of $10.33, implying a potential 26% downside from the current price. However, the acquisition provides a floor at around $14.00. Over the past 60 days, EPS estimates have increased by 7.3%, reflecting improved analyst sentiment as the company nears the transaction's completion.
Revenue estimates have remained relatively stable during this period. The primary concern for shareholders is whether the third-quarter results will support the deal's timeline or raise concerns before regulatory approvals and the shareholder vote. Any significant deviation from expectations could influence sentiment surrounding the transaction, despite the all-cash offer offering some downside protection.
Investors will closely examine Organon's performance in its women's health portfolio. The company recently secured FDA approval for MIUDELLA, an intrauterine contraceptive device without hormones, and is presenting clinical data on VTAMA cream for atopic dermatitis at industry conferences. These pipeline developments and product launches are crucial to Sun Pharma's rationale for acquiring Organon.
Profitability metrics will also be of interest, as Organon has maintained a 53.7% gross profit margin despite a 3.2% decline in revenue over the past year. However, operating income has decreased more sharply. Whether the company can sustain margins through the deal's completion will be a key indicator of the health of the business Sun Pharma is set to acquire.
Organon's previous report disappointed, with earnings of $0.85 per share, falling short of the $0.90 consensus estimate by 5.6%. Revenue of $1.60 billion slightly exceeded expectations, resulting in a modest positive surprise. Monday's results will serve as one of the final quarterly snapshots before Organon becomes part of Sun Pharma's portfolio, serving as both a validation of the acquisition thesis and an assessment of standalone performance.
Rewritten by urgent.news; may contain errors — check the original.
Source: investing.com